The firm's amicus brief that it filed in SCOTUS on behalf of 16 leading medical & public health organizations in an effort to preserve access to mifepristone was mentioned in a @NYTimes op-ed piece written by @AmerMedicalAssn's Jack Resneck Jr.: bit.ly/3ox0z9k